Location: Room 3102

ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology.

[Latest Update]
We are excited to announce a significant breakthrough and the expansion of our pipeline at Asia Bio. In addition to our existing pipeline, ZTI has initiated the development of novel drugs incorporating antibodies as target moieties. The ZTI-201A pipeline, utilizing HER2-the most renowned and widely employed antibody in the ADC industry-targets breast cancer.

This expansion of our pipeline, made possible by leveraging TERACARRIER™, our platform technology for drug delivery systems, aims to overcome the limitations of the ADC industry. It is poised to emerge as a highly effective treatment option for patients with low HER2-expressed breast cancer.

[Pipeline]
ZTI-101 utilizes 177Lu for orphan disease (ovarian cancer), targeting IND approval this year. ZTI-102S is using 225Ac, which is Targeted Alpha Therapy (TAT) with strong therapeutic activity, overcoming the technically challenging delivery of high-energy alpha daughters through TERACARRIER™ technology. TERACARRIER™'s versatile platform extends to the new targeting agent applied pipeline, designed for solid tumor treatment using from small molecule to antibody. Our new pipeline ZTI-201A is using anti-HER2 antibody for HER2 low expressed breast cancer patient.

[Stage]
Nonclinical Stage for ZTI-101(Lu-177, Ovarian Cancer, ODD), Optimizing stage for ZTI-102S(TAT, Ac-225) and ZTI-201A (HER2, Breast Cancer).

[Patent]
The patented platform and the patented synthesizer equipment empower us to fully harness the potential of radiopharmaceuticals, marking a significant advancement in cancer treatment.

[Financial Growth]
We are currently ongoing efforts to secure $15 million in Series B funding. We are also strategically planning an IPO in 2025.

Jaden Hyungseok ChangCEO at ZTI BiosciencesSpeaker

Agenda Sessions

At this event

See Jaden Hyungseok at Asia Bio Partnering Forum

Jaden Hyungseok Chang
CEO at ZTI Biosciences
Speaker